Clinical and Molecular Hepatology

"Oxidative stress"

Research Letter

Early oxidative protein modifications and gut damage/leakiness contribute to drug-induced acute liver failure: Wiramon Rungratanawanich, Ying Qu, Andrew Holmes, Neil Kaplowitz, Byoung-Joon Song; Clin Mol Hepatol 2026;32(1):e29-e33.
Published online August 4, 2025; DOI: https://doi.org/10.3350/cmh.2025.0748

Citations

Citations to this article as recorded by

Tissue-derived extracellular vesicles–mediated delivery of a hepatic enzyme living panorama (HELP) for treating multifactorial liver diseases
Xin Zeng, Wei Jiang, Baohong He, Lan Li, Tian Wu, Fudong Fu, Han Yao, Guangneng Liao, Chengshi Wang, Dongbo Wu
Journal of Nanobiotechnology.2026;[Epub] CrossRef

2,376 View
106 Download
Crossref

Review

Liver fibrosis, cirrhosis, and portal hypertension

Stem cell exosomes: new hope and future potential for relieving liver fibrosis: Lihua Li, Yongjie Liu, Kunpeng Wang, Jinggang Mo, Zhiyong Weng, Hao Jiang, Chong Jin; Clin Mol Hepatol 2025;31(2):333-349.
Published online November 7, 2024; DOI: https://doi.org/10.3350/cmh.2024.0854

Abstract
PDF

Liver fibrosis is a chronic liver injury resulting from factors like viral hepatitis, autoimmune hepatitis, non-alcoholic steatohepatitis, fatty liver disease, and cholestatic liver disease. Liver transplantation is currently the gold standard for treating severe liver diseases. However, it is limited by a shortage of donor organs and the necessity for lifelong immunosuppressive therapy. Mesenchymal stem cells (MSCs) can differentiate into various liver cells and enhance liver function when transplanted into patients due to their differentiation and proliferation capabilities. Therefore, it can be used as an alternative therapy for treating liver diseases, especially for liver cirrhosis, liver failure, and liver transplant complications. However, due to the potential tumorigenic effects of MSCs, researchers are exploring a new approach to treating liver fibrosis using extracellular vesicles (exosomes) secreted by stem cells. Many studies show that exosomes released by stem cells can promote liver injury repair through various pathways, contributing to the treatment of liver fibrosis. In this review, we focus on the molecular mechanisms by which stem cell exosomes affect liver fibrosis through different pathways and their potential therapeutic targets. Additionally, we discuss the advantages of exosome therapy over stem cell therapy and the possible future directions of exosome research, including the prospects for clinical applications and the challenges to be overcome.

Citations

Citations to this article as recorded by

Sarcopenia and MASLD: novel insights and the future
Chang-Hai Liu, Qing-Min Zeng, Won Kim, Seung Up Kim, Zobair M. Younossi, Giovanni Targher, Christopher D. Byrne, Christos S. Mantzoros, Phunchai Charatcharoenwitthaya, Isabelle Anne Leclercq, Manuel Romero-Gómez, Hong Tang, Ming-Hua Zheng
Nature Reviews Endocrinology.2026; 22(3): 139. CrossRef
The Potential of Neural Stem Cell-derived Exosomes for the Treatment of Ischemic Stroke
Xu Deng, Xixiang Xie, Tao Zhu, Chunxia Chen
Stem Cell Reviews and Reports.2026; 22(2): 803. CrossRef
Immune System and Hepatic Stellate Cells’ Crosstalk in Liver Fibrosis: Pathways and Therapeutic Potential
Wahyu Widowati, Adilah Hafizha Nur Sabrina, Annisa Firdaus Sutendi, Fadhilah Haifa Zahiroh, Aris Muhamad Nurjamil, Teresa Liliana Wargasetia, Ita Margaretha Nainggolan, Rizal Azis, Elham Rismani, Massoud Vosough, Poorani Gurumallesh Prabu
Journal of Immunology Research.2026;[Epub] CrossRef
Modulation of PRL-1 in placental MSCs: A novel therapeutic strategy for hepatic fibrosis: Editorial on “Modulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the transition between epithelial-to-mesenchymal t
Lihai Jiang, Wenjie Zheng
Clinical and Molecular Hepatology.2026; 32(1): 377. CrossRef
Liver Fibrosis: Current Treatments, Bottlenecks, and Future Prospects for Translational Medicine
Dileep G. Nair, Ralf Weiskirchen
Sci.2026; 8(1): 9. CrossRef
Therapeutic potential of TMSC-Exo for non-alcoholic fatty liver disease using the liver-on-a-chip model
Shujiao He, Kexin Wang, Binghui Li, Wei Fang, Xinyi Wei, Fen Yao, Nan Wang, Xiaoxia Wang, Ying Zhang, Yi Gao, Yang Li, Shao Li, Shuqin Zhou, Juan Du, Qing Peng
Journal of Translational Internal Medicine.2026; 14(1): 134. CrossRef
The therapeutic potential of different mesenchymal stem cells and their derived exosomes in metabolic dysfunction-associated steatotic liver disease
Dan Qin, Pingping Huang, Jialing Chen, Changjun Wu, Yuzhen Liang
Frontiers in Endocrinology.2025;[Epub] CrossRef
Stem cells therapies for liver diseases: for current practice and future goals
Yunbo Xie, Ziying Zhang, Yuefei Pan, Fu-Sheng Wang
Hepatology International.2025; 19(5): 1051. CrossRef
Human Umbilical Cord Blood Plasma‐Derived Exosomal miR‐410‐3p Alleviates Liver Injury by Regulating the Mitochondria‐Mediated Antiapoptotic Signaling
Lin Zhang, Yushuang Ren, Dongsheng Su, Qingyuan Jiang, Huan Peng, Fuyi Cheng, Hantao Zhang, Xue Bai, Xiao Wei, Weixiao Yang, Pusong Zhao, Yixin Ye, Gang Shi, Hongxin Deng
MedComm.2025;[Epub] CrossRef
Progress in antisenescence biomaterials for improved osteoarthritis therapy
Yang-Shuo Ge, Jia-Ying Ding, Jun Shen, Ting-Ting Meng, Chun-Meng Huang, Wen-Yao Li, Min-Jun Zhao, Jian-li Yin, Yu-Qing Zhai, Xue-Zong Wang, Jian-Guang Xu, Wenguo Cui, Dao-Fang Ding
Acta Biomaterialia.2025; 205: 81. CrossRef
Exosome Carrying OCT4/miR‐1246/β‐catenin Deriving From HBV Infected Hepatocytes Accelerated Liver Fibrosis
Tiantian Zhu, Yuankun Chen, Mingyue Niu, Qionghan He, Minhua Weng, Zheng Wang, Wenting Li
Journal of Biochemical and Molecular Toxicology.2025;[Epub] CrossRef
Integrating Network Pharmacology, Molecular Docking, and Experimental Validation: Andrographolide Attenuates Acute Liver Injury via the NLRP3/Caspase-1/GSDMD-Mediated Pyroptosis Pathway
Yankun Zhang, Shuanghui Liu, Xiaoxia Liang, Lizi Yin, Changliang He
Biomolecules.2025; 15(12): 1743. CrossRef
Cell-specific roles of autophagy in liver fibrosis: implications for targeted pharmacotherapy
Chibo Liu, Huan Yang, Yongjie Liu, Min An, Zhiyong Weng, Lihua Li
Annals of Medicine.2025;[Epub] CrossRef
Emerging nanomedicine for liver diseases treatment
Yawen Zhu, Dongxue Ge, Jinglin Wang, Hao Sun, Wei Li, Haozhen Ren
Journal of Nanobiotechnology.2025;[Epub] CrossRef

13,614 View
459 Download
13 Web of Science
Crossref

Special topic: Alcoholic liver diseases
The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Alcohol-related liver disease

Emerging medical therapies for severe alcoholic hepatitis: David Tornai, Gyongyi Szabo; Clin Mol Hepatol 2020;26(4):686-696.
Published online September 28, 2020; DOI: https://doi.org/10.3350/cmh.2020.0145

Abstract
PDF

Severe alcoholic hepatitis (AH) is an acute and often devastating form of alcohol-associated liver disease. Clinically, AH is characterized by elevated bilirubin, model for end stage liver disease scores >20, and nonspecific symptoms that are caused by underlying inflammation, hepatocyte injury, and impaired intestinal barrier function. Compromised immune defense in AH contributes to infections, sepsis and organ failure. To date, corticosteroids are the only recommended treatment for severe AH, however it does not provide survival benefits beyond 1 month. Recent preclinical and early clinical studies in AH aided understanding of the disease and presented opportunities for new therapeutic options targeting inflammation, oxidative stress, liver regeneration and modification of intestinal microbiota. In this comprehensive review, we discuss promising preclinical results and ongoing clinical trials evaluating novel therapeutic agents for the treatment of severe AH.

Citations

Citations to this article as recorded by

Chronic alcohol and liver health: The gut-liver axis as a therapeutic target
Dakshina M. Nair, Leela Kakithakara Vajravelu, Poornima Baskar Vimala, Rahul Harikumar Lathakumari, Vishnupriya Paneerselvam, Jayaprakash Thulukanam
Gastroenterology & Endoscopy.2026; 4(1): 38. CrossRef
Therapeutic potential of gallic acid and diosgenin in metabolic dysfunction-associated steatotic liver disease (MASLD) and non-alcoholic fatty liver disease (NAFLD): A comprehensive review
Trilochan Satapathy, Mansi Verma, Poonam Sahu, Anjali Minj
Pharmacological Research - Natural Products.2026; 10: 100525. CrossRef
Therapeutic Mechanisms of Lactiplantibacillus plantarum NXU0014 Against Chronic Alcohol‐Induced Liver Injury Mediated by Gut‐Liver Axis Modulation
Quan Ji, Yanhong Wang, Longxuan Huo, Chen Qiao, Fuqi Li, Fan Yang, Lin Pan
Molecular Nutrition & Food Research.2026;[Epub] CrossRef
Prospective study on time-to-tertiary care in alcohol-associated hepatitis: space–time coordinates as prognostic tool and therapeutic target
Ľubomír Skladaný, Daniela Žilinčanová, Natália Kubánek, Svetlana Adamcová Selčanová, Daniel Havaj, Lukáš Laffers, Michal Žilinčan, Alvi H Islam, Juan Pablo Arab, Tomáš Koller
Alcohol and Alcoholism.2025;[Epub] CrossRef
Larsucosterol for the Treatment of Alcohol-Associated Hepatitis
Mitchell Shiffman, Ben Da, Aparna Goel, Allison Kwong, Lance Stein, Christophe Moreno, Amanda Nicoll, Ashwini Mehta, Alexandre Louvet, Steven Flamm, Nikolaos Pyrsopoulos, Sanjaya Satapathy, Alexander Kuo, Daniel Ganger, Costica Aloman, Simone I. Strasser,
NEJM Evidence.2025;[Epub] CrossRef
Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
Xiao Ma, Tengda Huang, Xiangzheng Chen, Qian Li, Mingheng Liao, Li Fu, Jiwei Huang, Kefei Yuan, Zhen Wang, Yong Zeng
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
New prognostic model for hospitalized patients with alcoholic cirrhosis and Maddrey’s discriminant function <32
Tae Hyung Kim, Hyung Joon Yim, Young Kul Jung, Do Seon Song, Eileen L. Yoon, Hee Yeon Kim, Seong Hee Kang, Young Chang, Jeong-Ju Yoo, Baek Gyu Jun, Sung Won Lee, Jung Gil Park, Ji Won Park, Sung-Eun Kim, Tae Yeob Kim, Soung Won Jeong, Ki Tae Suk, Moon You
Hepatology International.2024; 18(2): 500. CrossRef
Review article: Hepatic steatosis and its associations with acute and chronic liver diseases
Aaron B. Koenig, Albert Tan, Hala Abdelaal, Fanny Monge, Zobair M. Younossi, Zachary D. Goodman
Alimentary Pharmacology & Therapeutics.2024; 60(2): 167. CrossRef
Pathogenesis of Alcohol-Associated Liver Disease
Pranoti Mandrekar, Abhishek Mandal
Clinics in Liver Disease.2024; 28(4): 647. CrossRef
3PM-guided innovation in treatments of severe alcohol-associated hepatitis utilizing fecal microbiota transplantation
Lubomir Skladany, Natalia Kubanek, Svetlana Adamcova Selcanova, Daniela Zilincanova, Daniel Havaj, Karolina Sulejova, Katarina Soltys, Lucia Messingerova, Michal Lichvar, Lukas Laffers, Michal Zilincan, Eva Honsova, Peter Liptak, Peter Banovcin, Jan Bures
EPMA Journal.2024; 15(4): 677. CrossRef
Alcohol-Related Liver Disease Including New Developments
Parita Virendra Patel, Steven L. Flamm
Clinics in Liver Disease.2023; 27(1): 157. CrossRef
Role of rifaximin in the management of alcohol‐associated hepatitis: A systematic review and meta‐analysis
Zohaib Ahmed, Joyce Badal, Mohamad Nawras, Dhanushya Battepati, Umer Farooq, Syeda Faiza Arif, Wade Lee‐Smith, Muhammad Aziz, Umair Iqbal, Ahmad Nawaz, Manesh Kumar Gangwani, Amna Iqbal, Abdallah Kobeissy, Benyam D Addissie, Mona Hassan, Sammy Saab
Journal of Gastroenterology and Hepatology.2023; 38(5): 703. CrossRef
Current and emerging therapies for alcohol-associated hepatitis
Francisco Idalsoaga, Gustavo Ayares, Luis Antonio Díaz, Jorge Arnold, María Ayala-Valverde, David Hudson, Marco Arrese, Juan Pablo Arab
Liver Research.2023; 7(1): 35. CrossRef
Tgr5 −/− mice are protected from ethanol-induced metabolic alterations through enhanced leptin and Fgf21 signaling
Sabita Pokhrel, Matthew Dilts, Zachary Stahl, Shannon Boehme, Gabrielle Frame, John Y.L. Chiang, Jessica M. Ferrell
Hepatology Communications.2023;[Epub] CrossRef
Therapeutic targets in alcohol-associated liver disease: progress and challenges
Ayooluwatomiwa Deborah Adekunle, Adeyinka Adejumo, Ashwani K. Singal
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
A Review on “IL-1 Receptor Antagonist Plus Pentoxifylline and Zinc for Severe Alcohol-Associated Hepatitis”
Shrihari Anikhindi, Akshay Anikhindi, Ashish Kumar, Anil Arora
Journal of Clinical and Experimental Hepatology.2023; 13(3): 533. CrossRef
A novel score of IL-13 and age predicts 90-day mortality in severe alcohol-associated hepatitis: A multicenter plasma biomarker analysis
David Tornai, Mack Mitchell, Craig J. McClain, Srinivasan Dasarathy, Arthur McCullough, Svetlana Radaeva, Aimee Kroll-Desrosiers, JungAe Lee, Bruce Barton, Gyongyi Szabo
Hepatology Communications.2023;[Epub] CrossRef
Current Medical Treatment for Alcohol-Associated Liver Disease
Gustavo Ayares, Francisco Idalsoaga, Luis A. Díaz, Jorge Arnold, Juan P. Arab
Journal of Clinical and Experimental Hepatology.2022; 12(5): 1333. CrossRef
Transplant in acute alcoholic hepatitis: a relative contraindication
Neha Jakhete, Ameer Abutaleb, Kirti Shetty
Current Opinion in Organ Transplantation.2022; 27(2): 93. CrossRef
Mesenchymal stem cells-based therapy in liver diseases
Heng-Tong Han, Wei-Lin Jin, Xun Li
Molecular Biomedicine.2022;[Epub] CrossRef
The role of gut microbiota in liver regeneration
Zhe Xu, Nan Jiang, Yuanyuan Xiao, Kefei Yuan, Zhen Wang
Frontiers in Immunology.2022;[Epub] CrossRef
Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives
Yoonji Ha, Inju Jeong, Tae Hyun Kim
Biomedicines.2022; 10(10): 2530. CrossRef
Innate immune activation: Parallels in alcohol use disorder and Alzheimer’s disease
Adriana Ramos, Radhika S. Joshi, Gyongyi Szabo
Frontiers in Molecular Neuroscience.2022;[Epub] CrossRef
Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives
Szu-Yi Liu, I-Ting Tsai, Yin-Chou Hsu
International Journal of Molecular Sciences.2021; 22(10): 5170. CrossRef

12,246 View
243 Download
22 Web of Science
Crossref

Reviews

NADPH oxidase mediated oxidative stress in hepatic fibrogenesis: Yong-Han Paik, David A. Brenner; Korean J Hepatol 2011;17(4):251-257.
Published online December 26, 2011; DOI: https://doi.org/10.3350/kjhep.2011.17.4.251

Abstract
PDF

NADPH oxidase (NOX) is a multicomponent enzyme complex that generates reactive oxygen species (ROS) in response to a wide range of stimuli. ROS is involved as key secondary messengers in numerous signaling pathways, and NADPH oxidases complex has been increasingly recognized as key elements of intracellular signaling of hepatic fibrogenesis. In the liver, NADPH oxidase is functionally expressed both in the phagocytic form and in the non-phagocytic form. The non-phagocytic NADPH oxidase complex is structurally and functionally similar to the phagocytic NADPH, resulting in reduction of molecular oxygen to generate superoxide. There are six homologous NOX proteins in the non-phagocytic forms of NADPH oxidase. An emerging concept is that both phagocytic and nonphagocytic NADPH oxidase components in hepatic stellate cells (HSCs) mediate hepatic fibrosis, suggesting its potential role as a pharmacological target for anti-fibrotic therapy. The molecular components and signaling pathways of various NADPH oxidase homologues that are critical for the fibrotic activity in HSCs need to be more clearly identified.

Citations

Citations to this article as recorded by

Immune System and Hepatic Stellate Cells’ Crosstalk in Liver Fibrosis: Pathways and Therapeutic Potential
Wahyu Widowati, Adilah Hafizha Nur Sabrina, Annisa Firdaus Sutendi, Fadhilah Haifa Zahiroh, Aris Muhamad Nurjamil, Teresa Liliana Wargasetia, Ita Margaretha Nainggolan, Rizal Azis, Elham Rismani, Massoud Vosough, Poorani Gurumallesh Prabu
Journal of Immunology Research.2026;[Epub] CrossRef
Beyond M1/M2: The role of reactive oxygen species in liver fibrosis and immune modulation
Huilun Lu, Jie Huang, Ya-chao Wang, Eudald Casals, Gregori Casals, Muling Zeng
Redox Biology.2025; 88: 103933. CrossRef
Advancements in gene therapy approaches for atrial fibrillation: Targeted delivery, mechanistic insights and future prospects
Roomana Khawajakhail, Rizwan Ullah Khan, Muhammad Umer Riaz Gondal, Hamza Khan Toru, Maria Malik, Arham Iqbal, Jahanzeb Malik, Maria Faraz, Muhammad Awais
Current Problems in Cardiology.2024; 49(4): 102431. CrossRef
Alcohol-Associated Liver Disease Outcomes: Critical Mechanisms of Liver Injury Progression
Natalia A. Osna, Irina Tikhanovich, Martí Ortega-Ribera, Sebastian Mueller, Chaowen Zheng, Johannes Mueller, Siyuan Li, Sadatsugu Sakane, Raquel Carvalho Gontijo Weber, Hyun Young Kim, Wonseok Lee, Souradipta Ganguly, Yusuke Kimura, Xiao Liu, Debanjan Dha
Biomolecules.2024; 14(4): 404. CrossRef
Insight into the regulation of the Nrf2 pathway in response to ascovirus infection in Spodoptera exigua
Ruoheng Jin, Zhengkun Xiao, Madoka Nakai, Guo‐Hua Huang
Pest Management Science.2023; 79(3): 1123. CrossRef
Pre‐clinical evidence of a dual NADPH oxidase 1/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis
Victor J. Thannickal, Karin Jandeleit‐Dahm, Cédric Szyndralewiez, Natalie J. Török
Journal of Cellular and Molecular Medicine.2023; 27(4): 471. CrossRef
Free Radicals and Oxidative Stress: Signaling Mechanisms, Redox Basis for Human Diseases, and Cell Cycle Regulation
Idris Zubairu Sadiq
Current Molecular Medicine.2023; 23(1): 13. CrossRef
Chronic exposure to nonylphenol induces oxidative stress and liver damage in male zebrafish (Danio rerio): Mechanistic insight into cellular energy sensors, lipid accumulation and immune modulation
Urmi Mukherjee, Anwesha Samanta, Subhasri Biswas, Soumyajyoti Ghosh, Sriparna Das, Sambuddha Banerjee, Sudipta Maitra
Chemico-Biological Interactions.2022; 351: 109762. CrossRef
Metformin Inhibits ROS Production by Human M2 Macrophages via the Activation of AMPK
Rana M. Nassif, Elias Chalhoub, Pia Chedid, Margarita Hurtado-Nedelec, Elia Raya, Pham My-Chan Dang, Jean-Claude Marie, Jamel El-Benna
Biomedicines.2022; 10(2): 319. CrossRef
NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook
Alberto Nascè, Karim Gariani, François R. Jornayvaz, Ildiko Szanto
Antioxidants.2022; 11(6): 1131. CrossRef
The construction of preclinical evidence for the treatment of liver fibrosis with quercetin: A systematic review and meta‐analysis
Xiaochuan Guo, Yuanyuan Li, Weizheng Wang, Luyao Wang, Sihan Hu, Xiaolin Xiao, Caiyu Hu, Yao Dai, Yiheng Zhang, Ziyu Li, Junlin Li, Xiao Ma, Jinhao Zeng
Phytotherapy Research.2022; 36(10): 3774. CrossRef
Alcoholic liver disease-from steatosis to cirrhosis - a biochemistry approach
Ruxandra Cioarca-Nedelcu, Valeriu Atanasiu, Irina Stoian
Journal of Medicine and Life.2021; 14(5): 594. CrossRef
Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis
Le Thi Thanh Thuy, Hoang Hai, Norifumi Kawada
Clinical and Molecular Hepatology.2020; 26(3): 280. CrossRef
Long‐Term Measures of Dyslipidemia, Inflammation, and Oxidative Stress in Rats Fed a High‐Fat/High‐Fructose Diet
Christine Feillet‐Coudray, Gilles Fouret, Claire Vigor, Béatrice Bonafos, Bernard Jover, Agnieszka Blachnio‐Zabielska, Jennifer Rieusset, François Casas, Sylvie Gaillet, Jean Francois Landrier, Thierry Durand, Charles Coudray
Lipids.2019; 54(1): 81. CrossRef
Gene therapy for atrial fibrillation - How close to clinical implementation?
Amar Trivedi, Jacob Hoffman, Rishi Arora
International Journal of Cardiology.2019; 296: 177. CrossRef
Melatonin application in targeting oxidative‐induced liver injuries: A review
Keywan Mortezaee, Neda Khanlarkhani
Journal of Cellular Physiology.2018; 233(5): 4015. CrossRef
Inhibition of autophagy reverses alcohol-induced hepatic stellate cells activation through activation of Nrf2-Keap1-ARE signaling pathway
Zheng-Yuan Xie, Zhi-Hua Xiao, Fen-Fen Wang
Biochimie.2018; 147: 55. CrossRef
Hepatoprotective effects of curcumin in rats after bile duct ligation via downregulation of Rac1 and NOX1
Zohreh-al-sadat Ghoreshi, Razieh Kabirifar, Fatemeh Safari, Alireza Karimollah, Ali Moradi, Ebrahim Eskandari-Nasab
Nutrition.2017; 36: 72. CrossRef
The effects of urotensin II on migration and invasion are mediated by NADPH oxidase-derived reactive oxygen species through the c-Jun N-terminal kinase pathway in human hepatoma cells
Ying-ying Li, Zheng-ming Shi, Xiao-tong Yu, Ping Feng, Xue-Jiang Wang
Peptides.2017; 88: 106. CrossRef
Baccharis trimerainhibits reactive oxygen species production through PKC and down-regulation p47phoxphosphorylation of NADPH oxidase in SK Hep-1 cells
Glaucy Rodrigues de Araújo, Ana Carolina Silveira Rabelo, Janaína Serenato Meira, Joamyr Victor Rossoni-Júnior, William de Castro-Borges, Renata Guerra-Sá, Maurício Azevedo Batista, Denise da Silveira-Lemos, Gustavo Henrique Bianco de Souza, Geraldo Célio
Experimental Biology and Medicine.2017; 242(3): 333. CrossRef
Quercetin protects liver injury induced by bile duct ligation via attenuation of Rac1 and NADPH oxidase1 expression in rats
Razieh Kabirifar, Zohreh-al-sadat Ghoreshi, Fatemeh Safari, Alireza Karimollah, Ali Moradi, Ebrahim Eskandari-nasab
Hepatobiliary & Pancreatic Diseases International.2017; 16(1): 88. CrossRef
Pigment Epithelium-Derived Factor (PEDF) Prevents Hepatic Fat Storage, Inflammation, and Fibrosis in Dietary Steatohepatitis of Mice
Takafumi Yoshida, Jun Akiba, Takanori Matsui, Kazuo Nakamura, Takao Hisamoto, Mitsuhiko Abe, Yu Ikezono, Fumitaka Wada, Hideki Iwamoto, Toru Nakamura, Hironori Koga, Sho-ichi Yamagishi, Takuji Torimura
Digestive Diseases and Sciences.2017; 62(6): 1527. CrossRef
Hybrid Nitric Oxide Donor and its Carrier for the Treatment of Peripheral Arterial Diseases
Duong Q. Le, Aneetta E. Kuriakose, Dat X. Nguyen, Kytai T. Nguyen, Suchismita Acharya
Scientific Reports.2017;[Epub] CrossRef
Caveolin 1-related autophagy initiated by aldosterone-induced oxidation promotes liver sinusoidal endothelial cells defenestration
Xiaoying Luo, Dan Wang, Xuan Luo, Xintao Zhu, Guozhen Wang, Zuowei Ning, Yang Li, Xiaoxin Ma, Renqiang Yang, Siyi Jin, Yun Huang, Ying Meng, Xu Li
Redox Biology.2017; 13: 508. CrossRef
Ursolic acid suppresses TGF-β1-induced quiescent HSC activation and transformation by inhibiting NADPH oxidase expression and Hedgehog signaling
Shan-Shan Yu, Biao Chen, Chen-Kai Huang, Juan-Juan Zhou, Xin Huang, An-Jiang Wang, Bi-Min Li, Wen-Hua He, Xuan Zhu
Experimental and Therapeutic Medicine.2017; 14(4): 3577. CrossRef
Isoniazid Induced Toxicities and Idiosyncratic Responses in Male Albino Wistar Rats
Solomon E. Owumi, Michael A. Gbadegesin, Fisayo A. Olotu, Oyeronke A. Odunola
Journal of Cancer Research Updates.2017;[Epub] CrossRef
Role of redoximiRs in fibrogenesis
Marta Fierro-Fernández, Verónica Miguel, Santiago Lamas
Redox Biology.2016; 7: 58. CrossRef
Is Liver Enzyme Release Really Associated with Cell Necrosis Induced by Oxidant Stress?
Martha Lucinda Contreras-Zentella, Rolando Hernández-Muñoz, Karina R. Gordillo
Oxidative Medicine and Cellular Longevity.2016;[Epub] CrossRef
Aging increases the susceptibility of hepatic inflammation, liver fibrosis and aging in response to high-fat diet in mice
In Hee Kim, Jun Xu, Xiao Liu, Yukinori Koyama, Hsiao-Yen Ma, Karin Diggle, Young-Hyun You, Jan M. Schilling, Dilip Jeste, Kumar Sharma, David A. Brenner, Tatiana Kisseleva
AGE.2016; 38(4): 291. CrossRef
Effects on intestinal microbiota and immune genes of Solea senegalensis after suspension of the administration of Shewanella putrefaciens Pdp11
Sara Vidal, Silvana Teresa Tapia-Paniagua, Jesús Miguel Moriñigo, Carmen Lobo, Inés García de la Banda, María del Carmen Balebona, Miguel Ángel Moriñigo
Fish & Shellfish Immunology.2016; 58: 274. CrossRef
Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation
Diptadip Dattaroy, Ratanesh Kumar Seth, Suvarthi Das, Firas Alhasson, Varun Chandrashekaran, Gregory Michelotti, Daping Fan, Mitzi Nagarkatti, Prakash Nagarkatti, Anna Mae Diehl, Saurabh Chatterjee
American Journal of Physiology-Gastrointestinal and Liver Physiology.2016; 310(7): G510. CrossRef
Dietary administration of the probiotic SpPdp11: Effects on the intestinal microbiota and immune-related gene expression of farmed Solea senegalensis treated with oxytetracycline
S.T. Tapia-Paniagua, S. Vidal, C. Lobo, I. García de la Banda, M.A. Esteban, M.C. Balebona, M.A. Moriñigo
Fish & Shellfish Immunology.2015; 46(2): 449. CrossRef
Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis
Diptadip Dattaroy, Sahar Pourhoseini, Suvarthi Das, Firas Alhasson, Ratanesh Kumar Seth, Mitzi Nagarkatti, Gregory A. Michelotti, Anna Mae Diehl, Saurabh Chatterjee
American Journal of Physiology-Gastrointestinal and Liver Physiology.2015; 308(4): G298. CrossRef
Exploring the Molecular Basis for Selective Binding of Homoserine Dehydrogenase from Mycobacterium leprae TN toward Inhibitors: A Virtual Screening Study
Dongling Zhan, Dongmei Wang, Weihong Min, Weiwei Han
International Journal of Molecular Sciences.2014; 15(2): 1826. CrossRef
Expression profiles of fetal membrane nicotinamide adenine dinucleotide phosphate oxidases (NOX) 2 and 3 differentiates spontaneous preterm birth and pPROM pathophysiologies
J. Polettini, M.G. Silva, M. Kacerovsky, T.A. Syed, G. Saade, R. Menon
Placenta.2014; 35(3): 188. CrossRef
Andrographis paniculata Leaf Extract Prevents Thioacetamide-Induced Liver Cirrhosis in Rats
Daleya Abdulaziz Bardi, Mohammed Farouq Halabi, Pouya Hassandarvish, Elham Rouhollahi, Mohammadjavad Paydar, Soheil Zorofchian Moghadamtousi, Nahla Saeed Al-Wajeeh, Abdulwali Ablat, Nor Azizan Abdullah, Mahmood Ameen Abdulla, Aamir Ahmad
PLoS ONE.2014; 9(10): e109424. CrossRef
Hypercholesterolemic diet induces hepatic steatosis and alterations in mRNA expression of NADPH oxidase in rat livers
Isabel Cristina Mallosto Emerich de Abreu, Joyce Ferreira da Costa Guerra, Renata Rebeca Pereira, Maísa Silva, Wanderson Geraldo de Lima, Marcelo Eustáquio Silva, Maria Lúcia Pedrosa
Arquivos Brasileiros de Endocrinologia & Metabologia.2014; 58(3): 251. CrossRef
Hepatocyte Growth Factor Protects Against Isoniazid/Rifampicin-Induced Oxidative Liver Damage
Cristina Enriquez-Cortina, Maylin Almonte-Becerril, Denise Clavijo-Cornejo, Mayrel Palestino-Domínguez, Oscar Bello-Monroy, Natalia Nuño, Anayelly López, Leticia Bucio, Verónica Souza, Rogelio Hernández-Pando, Linda Muñoz, María Concepción Gutiérrez-Ruiz,
Toxicological Sciences.2013; 135(1): 26. CrossRef
Expression and Function of Methylthioadenosine Phosphorylase in Chronic Liver Disease
Barbara Czech, Katja Dettmer, Daniela Valletta, Michael Saugspier, Andreas Koch, Axel P. Stevens, Wolfgang E. Thasler, Martina Müller, Peter J. Oefner, Anja-Katrin Bosserhoff, Claus Hellerbrand, Matias A Avila
PLoS ONE.2013; 8(12): e80703. CrossRef
Docosahexaenoic Acid Attenuates Hepatic Inflammation, Oxidative Stress, and Fibrosis without Decreasing Hepatosteatosis in a Ldlr Mouse Model of Western Diet-Induced Nonalcoholic Steatohepatitis
Christopher M. Depner, Kenneth A. Philbrick, Donald B. Jump
The Journal of Nutrition.2013; 143(3): 315. CrossRef
Diagnostic accuracy of biomarkers measured in the hepatic vein and peripheral vein in the prediction of advanced fibrosis in patients with chronic viral hepatitis
Ki Tae Suk, Dong Joon Kim, Chang Hoon Kim, Seung Ha Park, Jae Youn Cheong, Sung Won Cho, Jong Young Choi, Kwang Hyub Han, Ho Taik Sung, So Hyung Hong, Dae Yong Kim, Jai Hoon Yoon, Yeon Soo Kim, Gwang Ho Baik, Jin Bong Kim
Clinical Biochemistry.2012; 45(13-14): 1075. CrossRef
Mesenchymal stem cells restore CCl4‐induced liver injury by an antioxidative process
Kyung‐Ah Cho, So‐Youn Woo, Ju‐Young Seoh, Ho‐Seong Han, Kyung‐Ha Ryu
Cell Biology International.2012; 36(12): 1267. CrossRef

12,382 View
79 Download
Crossref

Nonalcoholic steatohepatitis: Pathogenesis and treatment: Sang Hoon Park; Korean J Hepatol 2008;14(1):12-27.
Published online March 20, 2008; DOI: https://doi.org/10.3350/kjhep.2008.14.1.12

Abstract
PDF

Nonalcoholic fatty liver disease (NAFLD) is characterized by a wide spectrum of liver damage spanning steatosis, nonalcoholic steatohepatitis (NASH), cryptogenic liver cirrhosis, and even to hepatocellular carcinoma. Investigations in the last few years have focused on NASH, a relatively aggressive form of liver disease, due largely to the explosion of information provided by clinical and basic science studies related to the widespread presence of risk factors, such as obesity, type II diabetes mellitus, and dyslipidemia. This is especially important given that obesity and type II diabetes mellitus have recently reached epidemic proportions in Korea. The pathogenesis of NASH is multifactorial, with insulin resistance and increased fatty acid possibly being important factors in the accumulation of hepatocellular fat, and oxidant stress, lipid peroxidation, mitochondrial dysfunction, and dysregulation of variable cytokines possibly being important causes of hepatocellular injury in steatotic liver. Because not all steatotic livers progress to NASH, some other environmental factors or a combination of genetic factors are thought to be required for progression to NASH and fibrosis. Lifestyle modifications continue to be the cornerstone therapy in NAFLD, but some insulin-sensitizing drugs might be more effective in treating NASH. Many pilot trials for antioxidants and lipid-lowering and hepatic protective agents have yielded promising initial results in improving liver enzymes or features of liver histology. However, the efficacy of these agents remains questionable. Despite recent gains in understanding NASH, several issues related to its natural history, pathogenesis, and treatment remain unresolved. (Korean J Hepatol 2008;14:12- 27)

Citations

Citations to this article as recorded by

Elevated red cell distribution width is associated with advanced fibrosis in NAFLD
Hwa Mok Kim, Bum Soo Kim, Yong Kyun Cho, Byung Ik Kim, Chong Il Sohn, Woo Kyu Jeon, Hong Joo Kim, Dong Il Park, Jung Ho Park, Kwan Joong Joo, Chang Joon Kim, Yong Sung Kim, Woon Je Heo, Won Seok Choi
Clinical and Molecular Hepatology.2013; 19(3): 258. CrossRef
Validity and reliability of the nonalcoholic fatty liver diseases activity score (NAS) in Korean NAFLD patients and its correlation with clinical factors
Kyung-Hun Lee, Sang Hoon Park, Yu Jin Kim, Kyung Rim Huh, Kwang Seon Min, Sun-Young Jun, Kyoung Oh Kim, Cheol Hee Park, Taeho Hahn, Kyo-Sang Yoo, Jong Hyeok Kim, Myung-Seok Lee, Choong Kee Park
The Korean Journal of Hepatology.2010; 16(1): 29. CrossRef
Ko NOMURA
Environmental Education.2010; 20(1): 6. CrossRef
Pathology of nonalcoholic steatohepatitis
Yoon-Mi Jeen, So-Young Jin
The Korean Journal of Hepatology.2009; 15(2): 122. CrossRef
The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology
Stephen Caldwell, Sang H. Park
Journal of Gastroenterology.2009; 44(S19): 96. CrossRef

8,544 View
108 Download
Crossref

Original Article

Lipid Peroxidation in Chronic Liver Diseases Type B: Kyung Chul Kim , Kwan Sik Lee , Kwang Hyub Han , Won Choi , Chae Yoon Chon , Sang In Lee , Young Myung Moon , Jin Kyung Kang , In Suh Park , Hye Young Kim; Korean J Hepatol 1997;3(1):40-49.

Abstract
PDF

Background/Aims
.' Oxidative stress is known to play a role in the pathogenesis of a certain liver diseases such as alcoholic liver disease, metal storage disease, and ischemia/reperfusion injury. Recently oxidative stress(lipid peroxidation) has also been implicated in hepatic fibrosis, which is now regarded as a common response to chronic liver injury regardless of its nature. Development of fibrosis and cirrhosis are the major complications of chronic hepatitits B. So we aimed to detect lipid peroxidation in chronic hepatitis B and to investigate its potential role in the pathophysiology of the disease. Methods .' The subjects were histologically-proven 56 patients, including fatty liver(FL, n=8), healthy HBsAg carrier(n=6), chronic persistent hepatitis(CPH, n=8), mild chronic active hepatitis(CAH- m, n=10), severe CAH(CAH-s, n=16), and liver cirrhosis(LC, n=8). All patients were serologically HBsAg-positive except those with FL. Lipid peroxidation was detected in serum and liver specimen with TBARS(thiobarbituric acid-reacting substances) assay. Western blot and immunohistochemical stain of liver specimen were also performed, using polyclonal antibody against malondialdehyde (MDA). Results '. 1. There were no significant differences in serum TBARS levels among groups(p= 0.24). 2. The mean tissue TBARS level(nmol/g) was significantly higher in CAH-s group(175.4+ 41.5) than in other groups(FL 54.0+ 6.4, Carrier 51.1+ 15.9, CPH 63.9+ 2.9, CAH-m 68.9+ 7.9, LC 22.6+ 5.1) (p<0.05). 3. Tissue TBARS levels correlated with serum ALT levels(r=0.5934, p<0.05). 4. Western blot showed MDA bands only in CAH-s group. 5. Immunohistochemistry showed a strong MDA stain around portal and periportal area in CAH-s group, but weak or no stain in other groups. Conclusions . This study shows that lipid peroxidation can be detected in situ and commonly occurs in severe chronic hepatitis B. Oxidative stress may be related to active necroinflammatory change of the liver and contribute to the progression of the disease in chronic hepatitis B.